Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Amiselimod in Mild to Moderate Ulcerative Colitis
jRCT2031210352Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of amiselimod in autoimmune colitis (3 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Change from baseline in modified Mayo Score at Day 85. Started Feb 2022; status: completed.
02
Drugs
amiselimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031210352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210352.